Drugs for dengue: a patent review (2010 – 2014)

Bibliography

• Gubler DJ. The economic burden of dengue. Am J Trop Med Hyg 2012;86:743-4
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Field’s virology. 5th edition. Wolters Kluwer and Lippincott Williams & Wilkins; Philadelphia: 2007. p. 1101-52
   Google Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013;496:504-7
   PubMed Web of Science ®Google Scholar
• Dengue and dengue haemorrhagic fever. WHO Factsheet No117, 2014. Available from: www.who.int/mediacentre/factsheets/fs117/en/ [Last accessed 15 July 2014]
   Google Scholar
• Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002;10:100-3
   PubMedGoogle Scholar
• Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med 2009;9:152-73
   PubMed Web of Science ®Google Scholar
• Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010;8(12 Suppl):S7-S16
   PubMed Web of Science ®Google Scholar
• Gubler DJ. Cities spawn epidemic dengue viruses. Nat Med 2004;10:129-30
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Pat 2010;20:819-35
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Khanna N. Experimental dengue vaccines. In: Giese M, editor. Molecular vaccine-from prophylaxis to therapy. Springer-Verlag; Heidelberg: 2013. p. 135-51
   Google Scholar
• Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-67
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Khanna N, Herring B, Mahalingam S. Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 2013;13:191-2
   PubMed Web of Science ®Google Scholar
• Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010;85:450-62
   PubMed Web of Science ®Google Scholar
• Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 2013;100:500-19
   PubMed Web of Science ®Google Scholar
• Muller DA, Young PR. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res 2013;98:192-208
   PubMed Web of Science ®Google Scholar
• Yusof R, Clum S, Wetzel M, et al. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 2000;275:9963-9
   PubMed Web of Science ®Google Scholar
• Munoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signalling by dengue virus. Proc Natl Acad Sci USA 2003;100:14333-8
   PubMed Web of Science ®Google Scholar
• Filomatori CV, Lodeiro MF, Alvarez DE, et al. A 5’ RNA element promotes dengue virus RNA synthesis on a circular genome. Genes Dev 2006;20:2238-49
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3:13-22
   PubMed Web of Science ®Google Scholar
• Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antiviral Res 2009;81:6-15
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003;100:6986-91
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2011;75:7769-73
   Google Scholar
• Smit JM, Moesker B, Rodenhuis-Zybert I, Wilschut J. Flavivirus cell entry and membrane fusion. Viruses 2011;3:160-71
   PubMed Web of Science ®Google Scholar
• University of Rochester, New York. Compositions and methods for inhibition of or treatment of dengue virus infection. US0189275A1; 2013
   Google Scholar
• Van der Schaar HM, Rust MJ, Chen C, et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog 2008;4:e1000244
   PubMed Web of Science ®Google Scholar
• Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988;38:172-80
   PubMed Web of Science ®Google Scholar
• Guzmán MG, Kouri GP, Bravo J, et al. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990;42:179-84
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Greene S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9
   PubMed Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002;185:1213-21
   PubMed Web of Science ®Google Scholar
• Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol 2008;11:369-77
   PubMed Web of Science ®Google Scholar
• National University of Singapore. Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof. SG191155A1; WO2012/082073A1; US2013/0259871A1
   Google Scholar
• Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007;195:665-74
   PubMed Web of Science ®Google Scholar
• Agency for Science, Technology and Research, Singapore (SG). Binding molecules against dengue virus and uses thereof. WO089647A1; 2013
   Google Scholar
• Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 2007;45:3777-80
   PubMed Web of Science ®Google Scholar
• Wahala WM, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009;392:103-13
   PubMed Web of Science ®Google Scholar
• Nanyang Technological University (Singapore). Antibodies for diagnosis and treatment of flaviviral infections. WO093335A1; 2010
   Google Scholar
• Vachy R. D-Glucopyranose 1-[3, 5-Bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and uses thereof. US0016244A1; 2010
   Google Scholar
• Universitá Degli Studi Di Milano (IT), Consejo Superior De Investigaciones Cientificas (ES) & Universitè Joseph Fourier (FR). Inhibitors of microbial infections. WO000721A1; 2011
   Google Scholar
• Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007;39:505-28
   PubMed Web of Science ®Google Scholar
• De Rossi G, Whiteford JR. Novel insights into the biological functions of syndecan ectodomain core proteins. Biofactors 2013;39:374-82
   PubMed Web of Science ®Google Scholar
• Bacsa S, Karasneh G, Dosa S, et al. Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. J Gen Virol 2011;92:733-43
   PubMed Web of Science ®Google Scholar
• De Witte L, Bobardt M, Chatterji U, et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 2007;104:19464-9
   PubMed Web of Science ®Google Scholar
• Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surface of hepatocytes. J Virol 2013;87:6866-75
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-97
   PubMed Web of Science ®Google Scholar
• The Board of Regents of the Texas University System. Small molecule inhibitors of dengue and West Nile virus proteases. US0035284A1; WO134135A1; 2013
   Google Scholar
• Georgetown University (US). Flavivirus inhibitors and methods of their use. US0038962A1;2014
   Google Scholar
• University of Malaya. A medicament for treating dengue. MY142050A;2010
   Google Scholar
• Wang Q, Pang YP. Accurate reproduction of 161 small-molecule complex crystal structures using the EUDOC program: expanding the use of EUDOC to supramolecular chemistry. PLoS One 2007;2:e531
   Web of Science ®Google Scholar
• Tomlinson SM, Malmstrom RD, Russo A, et al. Structure-based discovery of dengue protease inhibitors. Antiviral Res 2009;82:110-14
   PubMed Web of Science ®Google Scholar
• Mogi T, Kita K. Gramicidin S and polymixins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci 2009;66:3821-6
   PubMed Web of Science ®Google Scholar
• McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action and resistance. Clin Microbiol Rev 1999;12:147-9
   PubMed Web of Science ®Google Scholar
• Yip KW, Ito E, Mao X, et al. Potential use of alexidinedihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther 2006;5:2234-40
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009;3:e381
   PubMed Web of Science ®Google Scholar
• Matusan AE, Pryor MJ, Davidson AD, Wright PJ. Mutagenesis of the dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. J Virol 2001;75:9633-43
   PubMed Web of Science ®Google Scholar
• Consiglio Nazionale Delle Richerche (Rome, IT), K. U. Leuven R&D (Leuven, BE) & Aix-Marseille Universite (Marseille, FR). Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections. US0208778A1; 2012
   Google Scholar
• Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010;85:39-58
   PubMed Web of Science ®Google Scholar
• De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011;51:1-24
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Hoffmann-La F, Roche AG. Method of treating dengue fever. CA2837242 A1; WO168348A1; 2012
   Google Scholar
• RFS Pharma LLC & Emory University. Purine monophosphate prodrugs for treatment of viral infections. CA2836579A1;2012
   Google Scholar
• RFS Pharma LLC & Emory University. Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections. WO091386A2; 2010
   Google Scholar
• Novartis AG (Basel). 2’-Branched nucleoside for treatment of viral infections. US0065101A1; 2014
   Google Scholar
• K. U. Leuven R&D. Antiviral activity of novel bicyclic heterocycles. US0190297A1; 2013
   Google Scholar
• Parodi AJ. Protein glucosylation and its role in protein folding. Annu Rev Biochem 2000;69:69-93
   PubMed Web of Science ®Google Scholar
• Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007;8:125-9
   PubMed Web of Science ®Google Scholar
• Institute for Hepatitis and virus research. Novel iminosugar derivatives demonstrate potent antiviral activity and reduced toxicity. US0189771A1; 2011
   Google Scholar
• University of Oxford, Oxford & United Therapeutics Corp. Iminosugars and methods of treating viral diseases. US0237567A1; 2013
   Google Scholar
• Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010;7:128-39
   PubMed Web of Science ®Google Scholar
• Samsa MM, Mondotte JA, Iglesias NG, et al. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog 2009;5:e1000632
   PubMed Web of Science ®Google Scholar
• Universidade Federal Do Ro De Janeiro (BR), Universidade De Lisboa (PT), Instituto De Medicina Molecular (PT). The DENV-derived peptides and methods for the inhibition of the flavivirus replication. WO159187A2; 2012
   Google Scholar
• Dana Farber Cancer Institute, Inc. & Harvard College (USA). Host-targeted inhibitors of dengue virus and other viruses. WO154778A1; 2013
   Google Scholar
• Weerapana E, Wang C, Simon GM, et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 2010;468:790-5
   PubMed Web of Science ®Google Scholar
• ZymoGenetics, Inc. Methods for treating viral infection using IL-28 and IL-29. US0020919A1; 2012
   Google Scholar
• Oregon Health & Science University (USA). siRNA useful in the treatment of flavivirus infection. WO012835A2; 2013
   Google Scholar
• Katholieke Universiteit Leuven (BE). Viral replication inhibitors. WO045516A1; 2013
   Google Scholar
• Tan GK, Ng JKW, Trasti SL, et al. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010;4:e672
   PubMed Web of Science ®Google Scholar
• Shanghai Institute Materia Medica. Use of quinazoline compound in preparation of anti-flavivirus drug. EP2649999A1;2013
   Google Scholar
• Biotron Ltd. 2-Naphthoyl-guanidine derivatives as antiviral agents. NZ564398A
   Google Scholar
• Byrd CM, Dai D, Jordan R, Hruby DE. Treatment and prevention of dengue virus infections. US0258079A1; 2012
   Google Scholar
• Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections. US0129677A1; 2013
   Google Scholar
• Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection. US0303491A1; 2013
   Google Scholar
• Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008;47:804-11
   PubMed Web of Science ®Google Scholar
• Malaria: Q&A on artemisinin resistance. Available from: http://www.who.int/malaria/media/artemisinin_resistance_qa/en/ [Last accessed 12 July 2014]
   Google Scholar
• U.S. Phytotherapy, Inc. Artemisinin with berberine compositions and methods of making. US102625; WO063271A1; 2013
   Google Scholar
• Humanitas Technology, LLC/Humanitas International Foundation. Antiviral compositions and methods of their use. US0012470A1; WO006795A2; 2013
   Google Scholar
• Talarico LB, Noseda MD, Ducatti DRB, et al. Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. J Gen Virol 2011;92:1332-42
   PubMed Web of Science ®Google Scholar
• Steele RL, Musso AF. Artemisinin-based combination therapy for treating viral mediated disease. US0011829A1; 2014
   Google Scholar
• Universiti Malaya (MY). Antiviral composition against flavivirus. WO147584A1; 2013
   Google Scholar
• Ranbaxy Lab Ltd (IN); International Centre for Genetic Engineering & Biotechnology (IN) & Department of Biotechnology (IN). Anti-dengue activity of Cissampelos pariera extracts. EP2389184; US 2012/0107424A1; WO 2010/084477A1; CN102361644(A)
   Google Scholar
• Whitehorn J, Vinh Chau NV, Truong NT, et al. Lovastatin for adult patients with dengue: protocol for a randomized controlled trial. Trials 2010;13:203
   Google Scholar
• Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010;4:e785
   PubMed Web of Science ®Google Scholar
• Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012;55:1216-24
   PubMed Web of Science ®Google Scholar
• Nguyen NM, Tran CNB, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013;207:1442-50
   PubMed Web of Science ®Google Scholar
• Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomized, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 2014;14(8):706-15
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s disease. Lancet Infect Dis 2003;3:722-7
   PubMed Web of Science ®Google Scholar
• Whitby K, Pierson TC, Geiss B, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005;79:8698-706
   PubMed Web of Science ®Google Scholar
• Rathore APS, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfold dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011;92:453-60
   PubMed Web of Science ®Google Scholar